The Review
On January 13, 2026, the FDA announced the results of a comprehensive review of 91 studies of GLP-1 receptor agonist peptides covering 107,910 patients.
The review didn't find an increased risk of suicidal ideation or behavior. The agency asked manufacturers to remove the warning from the labels of Saxenda, Wegovy, and Zepbound.
The Backup Data
The review followed earlier reports that came in once the peptides were on the market, the same reports that had prompted the warning in the first place.
That finding is consistent with FDA's broader 2026 review.
What this means
References2 sources
How to read these sources
This article uses primary sources and reviews to separate mechanism, human evidence, and context.
- Human Trial
Massachusetts Medical SocietySemaglutide and Cardiovascular Outcomes in Obesity without Diabetes Read source
Used Here ForGrounding the depression question in the SELECT trial's safety data.
Good ForSafety data from a large, long cardiovascular-outcomes trial of semaglutide 2.4 mg.
Not ForA definitive causal verdict on mood effects.
New England Journal of Medicine 389(24):2221-2232 - Public Update
FDA Drug Safety Communication
U.S. Food and Drug AdministrationFDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications Read source
Used Here ForGrounding the depression question in the FDA review that found no increased risk of suicidal thoughts or behavior with GLP-1 RA medications.
Good ForThe regulator's current assessment and the labeling change that followed.
Not ForA guarantee about any one person's mood; talk to a clinician about new or worsening symptoms.
FDA Drug Safety Communication, January 13, 2026